Novo Nordisk
Mentioned in 78 analyzed podcast episodes across 10 shows
A Danish pharmaceutical company and global leader in GLP-1 weight loss and diabetes drugs (Ozempic, Wegovy), commanding significant market share in the injectable market while facing competitive pressure from oral formulations and competitors like Eli Lilly. Recently announced substantial price cuts (up to 50%) for its flagship drugs starting 2027 following disappointing trial results and market competition, leading to significant stock declines. The company has pursued legal action against telehealth competitors offering compounded versions and faces multiple lawsuits over alleged inadequate safety warnings, making it a frequent topic in discussions about pharmaceutical pricing, competition, and regulatory challenges.
Mentioned On
Episode Mentions
Risky Bulletin · Jul 16, 2026
Srsly Risky Biz: Ransomware uses AI to amp up negotiations
“Major pharmaceutical company (Wegovy/GLP-1 maker) breached by Fulcrum Sec; data included proprietary AI models”
Networth and Chill with Your Rich BFF · Jul 15, 2026
How GLP-1s Are Reshaping the Economy and Who's Really Paying for It
“Manufacturer of Ozempic and Wagovi, GLP-1 drugs generating $71B in combined revenue with Monjaro in 2025”
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Oral obesity pill surpassed 3M prescriptions; new CEO Michael Dustar discussed company positioning amid Lilly competition”
REAL AF with Andy Frisella · Jun 16, 2026
1037. Andy, AJ (An0maly) & DJ CTI: UFC Freedom 250, Trump Announces US And Iran Reach Peace Deal & Elon Musk Becomes First Trillionaire
“Implied manufacturer of Ozempic/Manjaro weight-loss injectables discussed regarding pharmaceutical industry practices”
Pivot · Jun 9, 2026
Trump's AI Stake, SpaceX's IPO Froth, and Apple's Siri Overhaul
“Referenced as successful company that should be taxed progressively, not industry-specifically”
The Journal. · May 26, 2026
Novo Nordisk's CEO Has a Comeback Plan
“Danish pharmaceutical company and subject of episode; pioneered weight loss drug market with Ozempic and Wagovii but lost market share to Eli Lilly”
The Learning Leader Show With Ryan Hawk · May 24, 2026
689: Eric Ries - The Costco Hot Dog, Why Good Companies Go Bad, Financial Gravity, Building Incorruptible Organizations, and The Lean Startup's Unfinished Business
“Governed by nonprofit foundation; example of alternative governance structure protecting organizational mission”
The Dr. Gabrielle Lyon Show · May 19, 2026
The Cancer Doctors Keep Missing in Young Adults - Dr. Michelle Pearlman
“Manufacturer of GLP-1 medications including Ozempic, Wegovy, and Saxenda; discussed extensively regarding delivery systems and dosing”
Mind Pump: Raw Fitness Truth · May 16, 2026
2859: Take a Week Off and Gain 21% More Muscle — Here's the Science
“Produces semaglutide (Ozempic/Wegovy), competing in the rapidly expanding GLP-1 pharmaceutical market”
Rich Habits Podcast · May 14, 2026
Q&A: $1.3M IRA, Aging Parents & SpaceX's IPO
“Pharmaceutical company identified by AI-generated asset strategy for peptide market exposure”
Pharma and BioTech Daily · May 13, 2026
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
“Divested Parkinson's Cell Therapy Project (STEM PD) to Cellular Intelligence for regenerative medicine focus”
Rich Habits Podcast · May 8, 2026
Anthropic & SpaceX Partnership, GameStop Buying eBay & Data Centers In Your House
“Launching oral Ozempic pill available through Amazon Pharmacy for same-day delivery at $25-149/month”
The Ezra Klein Show · May 8, 2026
GLP-1s and the ‘Wild West’ of Wellness
“Manufacturer of semaglutide (Ozempic, Wegovy), the first major GLP-1 drug driving current adoption wave”
Pharma and BioTech Daily · May 7, 2026
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
“Advancing GLP amylin combo Cagrosima and obesity treatment Wegovi with $355M quarterly revenues despite technical setbacks”
Wall Street Breakfast · May 6, 2026
Soda & chips: McDonald's and AMD in focus
“Oral Wegovy success expected to offset sales declines in other product categories”
WSJ What’s News · May 6, 2026
Samsung Hits $1 Trillion Milestone as AI Demand Soars
“Weight-loss drug maker beat Q1 expectations with 30% sales surge, launching obesity pill with 2 million users despite Eli Lilly competition”
WSJ Minute Briefing · May 6, 2026
Samsung Joins The Trillion Dollar Club
“Maker of Wegovy obesity drug reported 30% Q1 sales surge and launched obesity pill with 2M prescriptions”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Obesity drug maker's WeGoV pill showing strong sales momentum, gaining market share against Eli Lilly with shares up 9%”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Weight loss pill achieved 2M+ US prescriptions in Q1, driving strong sales and stock gains despite Eli Lilly competition”
On The Pen GLP-1 News · May 5, 2026
He Took Retatrutide 40mg and Proved a Point
“Earnings call scheduled; competitor in GLP-1 market with Wegovy/Ozempic; referenced as market comparison point”
ZOE Science & Nutrition · Apr 30, 2026
Should you take Ozempic? The 5 things you need to know before starting GLP-1 drugs | Dr Ania Jastreboff
“Manufacturer of Ozempic (semaglutide) and Saxenda, key GLP-1 drugs discussed throughout episode”
Skin Anarchy · Apr 28, 2026
What “Efficacy” Actually Means in Skincare with Jack Jia of Musely
“Manufacturer of Ozempic, discussed as example of accidental wellness crossover and suboptimal business model for non-life-threatening conditions”
CNBC's "Fast Money" · Apr 24, 2026
Intel Posts Best Day Since 1987 and Counting Down to Big Tech Results 4/24/26
“Benefiting from Lilly's softer demand; valuation gap vs Lilly narrowing; 12x vs 26x multiples”
Pharma and BioTech Daily · Apr 24, 2026
Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily
“Announced positive clinical trial results for oral semiglutide extending beyond obesity to adolescent type 2 diabetes treatment”
Pharma and BioTech Daily · Apr 23, 2026
Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily
“Competing with Eli Lilly for dominance in oral GLP-1 weight loss drug market”
How I Invest with David Weisburd · Apr 22, 2026
E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)
“Competitor to Lilly in GLP-1 space; losing market share and facing low earnings multiples due to weak pipeline behind GLP-1.”
WSJ What’s News · Apr 22, 2026
Can a Chatbot Be Charged With Murder?
“Wegovy weight loss drug now available through Amazon's new pharmaceutical delivery program”
The AI Podcast · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major enterprise partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain”
Claude AI · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain by end of 2026”
Anthropic · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI to deploy AI across drug discovery, clinical trials, manufacturing, and supply chain with full deployment by end of 2026”
AI Breakdown · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain by end of 2026”
The Dr. Gabrielle Lyon Show · Apr 21, 2026
GLP-1 Side Effects, Risks, And Who Should Actually Be Using It | Dr. Christle Guevarra
“Manufacturer of semaglutide (Ozempic) and tirzepatide (Mounjaro/Zepbound), primary GLP-1 medications discussed”
CNBC's "Fast Money" · Apr 14, 2026
Big Tech Bounce… And An Economic Warning From JPMorgan CEO Jamie Dimon 4/14/26
“Partnering with OpenAI on AI for drug discovery; stock down 23% year-to-date despite partnership”
Armstrong & Getty On Demand · Apr 2, 2026
Oh My God I Hate The Left
“Manufacturer of Wegovy pill, competitor to Mounjaro with more restrictive dosing requirements”
PBS News Hour - Full Show · Apr 1, 2026
April 1, 2026 - PBS News Hour full episode
“Competitor in weight loss pharmaceutical market with Uygovy pill, which Foundayo follows as second daily oral medication”
Mad Money w/ Jim Cramer · Apr 1, 2026
Mad Money w/ Jim Cramer 4/1/26
“Competitor in GLP-1 weight loss pill market with slightly better efficacy but inferior convenience compared to Lilly's Foundail”
CNBC's "Fast Money" · Apr 1, 2026
Markets Rally Ahead of Trump’s Iran Address… And Fading The Bounce 4/1/26
“Oral Wegovy pill shows 17% weight loss efficacy, launched earlier in 2026, competing with Eli Lilly's Fondayo in GLP-1 market”
TBPN · Mar 28, 2026
Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN
“Pharmaceutical company using AI agents to shorten clinical trials”
TBPN · Mar 19, 2026
FULL INTERVIEW: Mark Cuban on Robots, AI, Self-Driving, and Advice to Students
“Mentioned alongside Eli Lilly for smart direct-to-patient GLP-1 strategies”
NPR News Now · Mar 5, 2026
NPR News: 03-05-2026 5PM EST
“GLP-1 drug Ozempic discussed in study showing reduced addiction risk in diabetes patients”
Danny Jones Podcast · Feb 27, 2026
#374 - Ex-Pharma Insider Exposes the $368 Billion Health Insurance Scam | Brigham Buhler
“GLP-1 manufacturer sued compounding pharmacies; lobbies FDA against peptide accessibility”
Marketplace All-in-One · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharmaceutical company cutting Ozempic and Wegovy prices by up to 50% amid FDA regulatory pressure on compounders”
Marketplace Morning Report · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharma company cutting Ozempic and Wegovy prices by up to 50% after Trump administration pricing deals; stock down 40%”
CNBC's "Fast Money" · Feb 24, 2026
Growing AI Warnings… And Opportunities in Private Credit & Real Estate 2/24/26
“Cutting Ozempic and Wegovia prices by 50% starting next year; stock down 3% on announcement”
NPR News Now · Feb 24, 2026
NPR News: 02-24-2026 6PM EST
“Announced price cuts for Ozempic and Wegovy starting 2027, reducing list prices to $675/month following disappointing trial results”
Morning Wire · Feb 24, 2026
Evening Wire: Cartel Pressure Continues & Mamdani’s Shovel Struggles | 2.24.26
“Announced plans to cut GLP-1 drug prices by up to 50% starting 2027 amid market competition”
Motley Fool Money · Feb 24, 2026
Party Like it’s 2027
“Pharmaceutical company in litigation with Hims & Hers over GLP-1 drug distribution and marketing”
Morning Brew Daily · Feb 24, 2026
Fictional Story Tanks Stock Market & The iPod Making a Comeback?
“Danish pharma company making Ozempic; stock plunged 14% after experimental obesity drug failed to match Eli Lilly's results in trials”
CNBC's "Fast Money" · Feb 23, 2026
Tariffs, Banks & Private Credit Jitters… And Crypto Below $65K 2/23/26
“Weight loss drug competitor down 16% on disappointing Cagrasema trial results, trading at five-year lows with zero value assigned to core business”
Dr. Bob Martin Show · Feb 23, 2026
Recharge Your Body Battery: Small Choices, Big Shifts in Everyday Health
“Mentioned as competitor in trillion-dollar weight loss drug market alongside Pfizer, Viking Therapeutics, and others”